PF-06480605 is a Monoclonal Antibody owned by Pfizer, and is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned.

PF-06480605 exhibits therapeutic intervention by blocking tumor necrosis factor (TNF)-like cytokine 1A (TL1A)/TNF superfamily member 15 (TNFSF15). TNFSF15 is a proinflammatory cytokine and TNF alpha superfamily member that is linked to inflammatory bowel disease (IBD). TL1A induces proinflammatory cytokines, including TNF alpha, from isolated human CD4+CD161+ T cells, whereas these cells were resistant to TNF alpha treatment. Thus anti-TNF alpha failed to block TL1A-induced cytokine production which significantly and selectively decreases the CD161 and TL1A expression thus helps in getting rid of the disease.

The revenue for PF-06480605 is expected to reach a total of $308m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PF-06480605 NPV Report.

PF-06480605 is originated and owned by Pfizer.

PF-06480605 Overview

PF-06480605 is under development for the treatment of moderate to severe ulcerative colitis. The drug candidate is a fully human immunoglobulin G1 monoclonal antibody, which is administered intravenously and subcutaneously. The drug candidate acts by targeting TNFSF15. It is a new molecular entity. It was also under development for Crohn's disease.

Pfizer Overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.

Quick View – PF-06480605

Report Segments
  • Innovator
Drug Name
  • PF-06480605
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.